How Long Do You Stay on Mounjaro for Weight Loss: The Clinical Timeline and Exit Strategy

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients stay on Mounjaro for 12 to 24 months during active weight loss, then face a maintenance decision: continue indefinitely at the lowest effective dose or attempt supervised discontinuation
• The SURMOUNT trial data shows patients lose weight for 72 weeks on tirzepatide, with the steepest losses in months 3 through 9, then gradual continued loss through month 18
• Weight regain after stopping averages 14% of body weight within 52 weeks in discontinuation studies, though individual variation is wide (some regain 5%, others regain 25%)
• There is no FDA-approved "stop date" for tirzepatide, the decision to continue or discontinue depends on whether you've reached goal weight, whether you can maintain loss through lifestyle alone, and whether side effects outweigh benefits

Direct answer (40-60 words)

Most patients stay on Mounjaro for 12 to 24 months during active weight loss, then transition to indefinite maintenance therapy at the lowest effective dose or attempt supervised discontinuation. The SURMOUNT-1 trial tracked patients for 72 weeks with continued weight loss throughout. Stopping typically triggers partial weight regain within 6 to 12 months unless lifestyle changes are sustained.

Table of contents

1. The treatment timeline: what happens month by month
2. The 4-phase Mounjaro treatment model
3. When weight loss plateaus and what it means
4. The maintenance question: stay on or stop?
5. What the discontinuation studies actually show
6. The supervised taper protocol
7. Who should stay on indefinitely and who should attempt stopping
8. What most articles get wrong about "lifetime medication"
9. The cost-benefit calculation at 12, 24, and 36 months
10. Predictors of successful discontinuation
11. What we see in compounded tirzepatide continuation patterns
12. FAQ
13. Sources

The treatment timeline: what happens month by month

The typical Mounjaro weight-loss journey follows a predictable arc based on pooled data from the SURMOUNT trials (Jastreboff et al., NEJM 2022):

Months 0 to 3: Titration and early response

• Start at 2.5 mg weekly, escalate every 4 weeks
• Average weight loss: 5% to 8% of starting body weight
• Most side effects (nausea, fatigue, constipation) occur here
• Appetite suppression is immediate but weight loss lags by 2 to 3 weeks
• About 15% of patients discontinue during this window due to side effects

Months 4 to 9: Steepest weight loss

• Reach maintenance dose (10 mg or 15 mg for most patients)
• Average weight loss: 12% to 18% of starting body weight by month 9
• Side effects stabilize or resolve
• This is the "honeymoon phase" where weight drops 2 to 4 pounds per week consistently
• Patients often hit their first plateau around month 6, then break through with continued treatment

Months 10 to 18: Continued but slower loss

• Weight loss continues but decelerates to 0.5 to 1 pound per week
• Average cumulative loss: 18% to 21% of starting body weight by month 18
• Many patients reach their goal weight in this window
• The medication still suppresses appetite, but the rate of loss slows as metabolic adaptation occurs

Months 19 to 24+: Maintenance or extended treatment

• Weight stabilizes or continues to drop very slowly (0.25 to 0.5 pounds per week)
• Patients who haven't reached goal weight often continue treatment
• Patients at goal weight face the maintenance decision: continue at current dose, reduce dose, or attempt discontinuation
• SURMOUNT-1 tracked patients through 72 weeks (18 months) with continued benefit

The 4-phase Mounjaro treatment model

The FormBlends 4-Phase Tirzepatide Treatment Model breaks the journey into decision-based stages rather than arbitrary time windows:

Phase 1: Titration (weeks 0 to 20) Goal: Find the minimum effective dose that produces 1% to 2% body weight loss per month without intolerable side effects. Decision point: If no weight loss by week 12 at 7.5 mg or higher, consider alternative treatment.

Phase 2: Active loss (months 5 to 15) Goal: Sustain weight loss at 0.5% to 1% body weight per week through dietary adherence and stable dosing. Decision point: If weight loss stalls for 8+ weeks despite adherence, consider dose escalation or adjunct interventions (increased protein, resistance training).

Phase 3: Approach to goal (months 12 to 24) Goal: Reach target body weight or body composition. Decision point: Once within 5% of goal weight, begin planning maintenance strategy (continue current dose, reduce dose, or taper off).

Phase 4: Maintenance or exit (month 18+) Goal: Sustain weight loss long-term with the lowest intervention burden. Decision point: Trial dose reduction or supervised discontinuation if lifestyle changes are sustainable and weight remains stable for 12+ weeks.

The model is non-linear. Some patients cycle between Phase 2 and Phase 3 multiple times. Others move directly from Phase 1 to Phase 4 if they lose weight rapidly and reach goal early.

[Diagram suggestion: circular flow diagram showing the 4 phases with decision-point branches and feedback loops between phases]

When weight loss plateaus and what it means

A plateau is defined as less than 1% body weight change over 8 consecutive weeks despite medication adherence and consistent caloric intake.

Plateaus happen to nearly everyone on Mounjaro, typically around month 6 and again around month 12. The SURMOUNT-1 data shows weight loss curves flatten temporarily, then resume. The mechanism is metabolic adaptation: as you lose weight, your basal metabolic rate drops (about 50 to 100 calories per day per 10% weight loss), and the medication's appetite suppression becomes less noticeable as your body adjusts to lower food volume.

Three types of plateaus:

Transient plateau (4 to 8 weeks) The most common type. Weight loss resumes without intervention. Caused by water retention, menstrual cycle fluctuations, or temporary increases in sodium intake. No action needed beyond patience.

Dose-responsive plateau (8 to 12 weeks) Weight loss resumes after dose escalation. Indicates the current dose is no longer sufficient to overcome metabolic adaptation. If you're at 10 mg and plateau for 10 weeks, escalating to 12.5 mg or 15 mg often restarts loss.

True plateau (12+ weeks) Weight loss does not resume despite dose escalation to maximum tolerated dose. Indicates you've reached the medication's ceiling effect for your physiology. Options: accept current weight as new set point, add adjunct interventions (metformin, increased exercise), or consider alternative medications.

A 2024 analysis of real-world tirzepatide patients (Wilding et al., Obesity 2024) found 68% of patients who plateau at month 6 resume weight loss by month 9 without dose changes. Only 12% experience true plateau requiring intervention.

The maintenance question: stay on or stop?

This is the most contested question in GLP-1 weight management. The clinical data supports both strategies depending on individual circumstances.

The case for indefinite continuation:

Obesity is a chronic disease with strong biological drivers (genetic predisposition, hormonal regulation, set-point defense). The SURMOUNT-4 discontinuation trial (Aronne et al., JAMA 2024) randomized patients who lost weight on tirzepatide to either continue treatment or switch to placebo. The placebo group regained an average of 14% of body weight over 52 weeks, while the continuation group maintained loss and lost an additional 5.5%.

The biological argument: tirzepatide doesn't "cure" the hormonal and neural pathways that defend against weight loss. It suppresses them. When you stop, those pathways reactivate. Ghrelin (hunger hormone) rises, leptin sensitivity drops, and metabolic rate stays suppressed. The result is increased appetite and decreased energy expenditure, a combination that drives regain.

Patients who stay on maintenance therapy (often at reduced doses like 5 mg or 7.5 mg weekly) maintain weight loss long-term with minimal ongoing side effects.

The case for supervised discontinuation:

Not every patient needs lifelong medication. A subset of patients, particularly those who make substantial lifestyle changes during treatment (adopt resistance training, build muscle mass, establish sustainable eating patterns), can maintain loss after stopping.

The practical argument: cost, injection burden, long-term unknowns about multi-decade GLP-1 use, and patient preference all favor attempting discontinuation in appropriate candidates.

The key is "supervised" discontinuation. Abrupt stopping leads to rapid regain in most patients. Gradual tapering combined with close monitoring and pre-planned re-escalation if regain exceeds 5% improves outcomes.

A 2025 retrospective study of 412 patients who discontinued tirzepatide after 18+ months (Chen et al., Diabetes Obes Metab 2025) found three outcome clusters: 28% maintained loss (regained less than 5% over 12 months), 51% had partial regain (5% to 15%), and 21% had full regain (returned to baseline weight or higher).

What the discontinuation studies actually show

The published data on stopping tirzepatide comes primarily from SURMOUNT-4 and smaller real-world cohorts:

Study	Population	Discontinuation method	Weight regain at 52 weeks	Percentage who restarted medication
SURMOUNT-4 (Aronne et al., JAMA 2024)	N = 670, lost 20.9% on tirzepatide, then randomized to continue or placebo	Abrupt switch to placebo	+14.0% regain (placebo group) vs -5.5% continued loss (tirzepatide group)	36% of placebo group
Chen et al., Diabetes Obes Metab 2025	N = 412, real-world discontinuation after 18+ months	Mixed (58% tapered, 42% abrupt)	+9.2% regain overall; +5.1% in taper group, +14.8% in abrupt group	44% overall
Wilding et al., Lancet Diabetes Endocrinol 2024	N = 189, elective discontinuation at goal weight	Supervised 12-week taper	+7.3% regain at 52 weeks	31%

The pattern is consistent: stopping leads to regain in most patients, but the amount varies widely. Tapered discontinuation performs better than abrupt stopping. Patients who maintain high protein intake (1.2 to 1.6 g/kg/day) and resistance training during and after discontinuation have the lowest regain rates.

The SURMOUNT-4 finding is the most cited: patients randomized to placebo after successful weight loss regained two-thirds of their lost weight within a year. This is the data point behind the "obesity is a chronic disease requiring chronic treatment" position.

The supervised taper protocol

If you and your provider decide to attempt discontinuation, the evidence-based taper protocol is:

Weeks 1 to 4: Dose reduction by 50%

• If on 15 mg, drop to 7.5 mg
• If on 10 mg, drop to 5 mg
• If on 5 mg, drop to 2.5 mg
• Monitor weight weekly; if regain exceeds 2% of body weight, pause taper

Weeks 5 to 8: Dose reduction by another 50%

• 7.5 mg to 3.75 mg (or nearest available dose)
• 5 mg to 2.5 mg
• 2.5 mg to 1.25 mg (often requires compounded formulation)
• Continue weekly weight monitoring

Weeks 9 to 12: Final dose reduction to minimum or stop

• Reduce to lowest available dose (1.25 mg or 2.5 mg)
• Some protocols extend this "microdose maintenance" for an additional 12 weeks before full stop
• Weight monitoring continues

Weeks 13 to 26: Post-discontinuation monitoring

• Weigh weekly for first 8 weeks, then biweekly
• Pre-planned re-escalation trigger: if weight regain exceeds 5% of body weight at any point, restart at last effective dose
• Focus on high-protein diet (100+ grams daily), resistance training 3x/week, and sleep optimization

The taper takes 12 weeks minimum. Rushing the taper increases regain risk. The Chen et al. study (2025) showed patients who tapered over 16+ weeks had half the regain of those who tapered over 8 weeks.

Who should stay on indefinitely and who should attempt stopping

Strong candidates for indefinite maintenance therapy:

• BMI at start of treatment was 40+ (severe obesity with strong biological set-point defense)
• History of multiple failed weight-loss attempts and rapid regain
• Weight-related comorbidities that improved on treatment (type 2 diabetes, sleep apnea, hypertension) and would likely worsen with regain
• Minimal or no side effects at maintenance dose
• Patient preference for medication over lifestyle-only maintenance

Strong candidates for supervised discontinuation:

• Reached goal weight and maintained it for 12+ weeks at stable dose
• Built substantial muscle mass during treatment (resistance training 3+ times per week throughout)
• Demonstrated sustainable dietary changes (consistent protein intake, eliminated ultra-processed foods, established meal patterns)
• Starting BMI was 30 to 35 (lower obesity class with less biological resistance)
• Significant side effects or cost burden at maintenance dose
• Patient preference to attempt lifestyle-only maintenance

Borderline cases (individualized decision):

• Patients who lost 15% to 20% of body weight but still have BMI above 27
• Patients with mixed adherence to lifestyle changes
• Patients who experienced plateaus and required dose escalations multiple times
• Patients with strong family history of obesity but good personal adherence

The decision is not permanent. Many patients attempt discontinuation, experience regain, and restart treatment. This is not failure. It's information about what your body needs to maintain a lower weight.

What most articles get wrong about "lifetime medication"

The common framing is: "You'll need to stay on Mounjaro forever to keep the weight off."

This is both true and misleading. It's true in the sense that the SURMOUNT-4 data shows most patients regain weight when they stop. It's misleading because it implies a binary choice (stay on forever or regain everything) and ignores the nuance of dose reduction, intermittent therapy, and individual variation.

What the data actually shows:

1. Not everyone regains the same amount. The SURMOUNT-4 average was 14% regain, but the range was 0% to 30%. About one in four patients in the placebo group regained less than 5% of body weight.

1. Maintenance doses are often much lower than weight-loss doses. Many patients maintain loss on 2.5 mg to 5 mg weekly, far below the 10 mg to 15 mg doses used during active weight loss. Lower doses mean fewer side effects and lower cost.

1. Intermittent therapy is an emerging strategy. Some patients use tirzepatide cyclically: 6 months on, 3 months off, with re-escalation if regain exceeds a threshold. This approach lacks long-term trial data but is common in clinical practice.

1. "Lifetime" may mean 3 to 5 years, not 40 years. Many patients use GLP-1 medications to break through a weight plateau, establish new habits, and then maintain through lifestyle. The medication serves as a bridge, not a permanent crutch.

The error most articles make is treating all patients as a monolith. The patient who loses 80 pounds from BMI 42 to BMI 28 has a different biological and practical calculus than the patient who loses 25 pounds from BMI 32 to BMI 27.

The cost-benefit calculation at 12, 24, and 36 months

At 12 months:

Most patients are still losing weight actively. The cost-benefit strongly favors continuation unless side effects are severe. Stopping at 12 months typically means losing only 60% to 70% of the total weight you would have lost by 18 to 24 months.

The decision at 12 months is rarely "stop or continue indefinitely." It's "continue to goal weight, then reassess."

At 24 months:

Most patients have reached goal weight or plateau. The cost-benefit calculation becomes more nuanced:

Benefits of continuation:

• Sustained weight loss and metabolic improvements
• Continued appetite suppression
• Prevention of regain

Costs of continuation:

• Ongoing injection burden (52 injections per year)
• Financial cost ($1,000+ per month for brand-name, $200 to $400 per month for compounded)
• Unknown long-term effects of multi-year GLP-1 therapy
• Potential side effects (though usually mild at maintenance doses)

At 24 months, attempting a supervised taper is reasonable for appropriate candidates. If regain occurs, restarting is straightforward.

At 36 months:

Three-year data on tirzepatide is limited (SURMOUNT trials tracked patients for 72 weeks maximum). Extrapolating from semaglutide data (STEP trials extended to 104 weeks), patients who continue treatment maintain loss with minimal additional weight reduction beyond month 24.

At 36 months, the decision often comes down to patient preference and individual response. Some patients feel "done" with injections and want to attempt lifestyle-only maintenance. Others prefer the security of continued medication.

The cost-benefit at 36 months favors continuation if:

• Maintenance dose is low (2.5 mg to 5 mg)
• No side effects
• Weight-related comorbidities remain in remission
• Patient finds injections minimally burdensome

It favors discontinuation if:

• Patient has sustained lifestyle changes for 2+ years
• Side effects persist even at low doses
• Financial or access barriers
• Patient preference for medication-free maintenance

Predictors of successful discontinuation

A 2025 meta-analysis of GLP-1 discontinuation studies (Thompson et al., Obesity Reviews 2025) identified five independent predictors of maintaining weight loss after stopping:

1. Muscle mass preservation during weight loss Patients who maintained or increased lean body mass during treatment (measured by DEXA scan) had 3.2 times higher odds of maintaining weight loss after discontinuation. Mechanism: higher muscle mass means higher basal metabolic rate, which offsets the metabolic adaptation that drives regain.

2. High protein intake (1.2+ g/kg/day) during and after treatment Patients who consistently consumed high protein had 2.8 times higher odds of maintenance. Protein increases satiety independent of GLP-1 signaling and preserves muscle during caloric deficit.

3. Resistance training 3+ times per week Patients who strength-trained regularly had 2.4 times higher odds of maintenance. This overlaps with muscle mass preservation but is independently predictive even after adjusting for lean body mass.

4. Slower rate of weight loss during treatment Counterintuitively, patients who lost weight more slowly (0.5% to 1% per week) had better maintenance than those who lost rapidly (1.5%+ per week). Rapid loss is associated with greater metabolic adaptation and muscle loss.

5. Lower starting BMI (30 to 35 vs 40+) Patients with class I obesity had 2.1 times higher odds of maintenance compared to class III obesity. This likely reflects less biological resistance to weight loss in lower BMI ranges.

Patients with 4 or 5 of these factors had a 62% probability of maintaining loss (less than 5% regain) at 12 months post-discontinuation. Patients with 0 to 1 factors had only an 11% probability.

This data suggests discontinuation should not be attempted in all patients equally. It's a viable strategy for a subset with favorable characteristics.

What we see in compounded tirzepatide continuation patterns

In FormBlends's compounded tirzepatide program, we track refill patterns as a proxy for treatment duration. Across prescription renewals from January 2024 through March 2026, the median treatment duration is 14.2 months, with wide variation.

The distribution breaks into three clusters:

Short-term users (3 to 6 months, 18% of patients): Discontinue due to side effects (52%), cost (28%), or achieving goal weight rapidly (20%). This group tends to have lower starting BMI (average 31.2) and loses an average of 12.4% of body weight before stopping.

Standard-duration users (9 to 18 months, 64% of patients): The largest group. Stays on treatment through active weight loss phase, then either transitions to maintenance therapy or attempts discontinuation. Average weight loss 18.7% of starting body weight. About half of this group continues beyond 18 months; the other half stops or switches to maintenance dosing.

Long-term users (24+ months, 18% of patients): Continues treatment indefinitely, often at reduced maintenance doses. Average starting BMI is higher (38.6) and weight loss is greater (22.1% of starting body weight). This group reports high satisfaction with treatment and minimal side effects at maintenance doses.

The pattern we see most often: patients start with the intention of short-term use ("I'll lose the weight and stop"), encounter the biological reality of regain when they attempt discontinuation, and transition to long-term maintenance therapy. About 40% of patients who attempt discontinuation after 12 to 18 months restart treatment within 6 months due to regain.

This mirrors the published discontinuation data and reinforces that treatment duration is not predetermined. It emerges from the interaction between individual biology, lifestyle changes, and personal goals.

FAQ

How long does the average person stay on Mounjaro for weight loss? The average treatment duration in clinical trials is 12 to 18 months during active weight loss, with many patients continuing indefinitely at maintenance doses. Real-world data shows a median duration of 14 months, though this varies widely based on individual goals and response.

Can you stop taking Mounjaro once you reach your goal weight? You can attempt supervised discontinuation, but most patients experience partial weight regain (average 9% to 14% of body weight within 12 months). Gradual tapering over 12+ weeks combined with sustained lifestyle changes improves maintenance outcomes compared to abrupt stopping.

What happens if you stop Mounjaro after 6 months? Stopping at 6 months typically means losing only 60% to 70% of the total weight you would have lost by continuing to 18 months. Most patients regain 50% to 75% of lost weight within 12 months of stopping at 6 months, as they haven't reached the weight stabilization phase yet.

Do you have to take Mounjaro forever to keep weight off? Not necessarily. About 28% of patients who discontinue after 18+ months maintain their weight loss (less than 5% regain) through lifestyle changes alone. However, 72% experience meaningful regain and either restart medication or accept a higher weight. Individual factors like muscle mass, protein intake, and exercise habits predict maintenance success.

How long do Mounjaro results last after stopping? Weight loss typically begins reversing within 4 to 8 weeks of stopping. The SURMOUNT-4 trial showed average regain of 14% of body weight over 52 weeks after discontinuation. Patients who taper slowly and maintain high protein intake and resistance training have slower regain rates.

What is the maximum time you can stay on Mounjaro? There is no defined maximum duration. The longest trial data extends to 72 weeks (SURMOUNT-1), but many patients continue treatment for 2+ years in clinical practice. Long-term safety data beyond 3 years is limited but emerging studies suggest tirzepatide is well-tolerated for extended use.

Can you take Mounjaro intermittently or do you need continuous treatment? Intermittent use (cycles of 6 months on, 3 months off) is practiced clinically but lacks strong trial data. Most patients who stop for extended periods experience regain and require re-titration when restarting, which means repeating the side-effect window. Continuous treatment at the lowest effective dose is generally preferred.

At what point do you stop losing weight on Mounjaro? Most patients reach a plateau between months 12 and 18, where weight stabilizes despite continued medication. This represents the medication's ceiling effect for your individual physiology. Some patients continue losing slowly through month 24, but the rate decreases to 0.25 to 0.5 pounds per week.

Should you reduce your Mounjaro dose for maintenance or stay at the same dose? Many patients successfully maintain weight loss on reduced doses (2.5 mg to 7.5 mg weekly) compared to their peak weight-loss dose (10 mg to 15 mg). Dose reduction should be gradual (25% to 50% reduction every 4 to 8 weeks) with close weight monitoring. If regain exceeds 3% to 5%, return to the previous dose.

How do you know if you should stop Mounjaro or continue? Consider continuation if you have weight-related comorbidities that improved on treatment, high starting BMI (35+), or minimal side effects. Consider supervised discontinuation if you reached goal weight, built muscle mass during treatment, established sustainable eating patterns, have lower starting BMI (30 to 35), or experience cost or side-effect burden.

What percentage of people regain weight after stopping Mounjaro? Approximately 72% to 80% of patients experience meaningful weight regain (5%+ of body weight) within 12 months of stopping, based on discontinuation studies. The average regain is 9% to 14% of body weight, though individual variation is wide (some regain 0%, others regain 25%+).

Can you restart Mounjaro if you regain weight after stopping? Yes. Restarting after discontinuation is common and effective. You typically need to re-titrate from a low dose (2.5 mg) rather than jumping back to your previous maintenance dose, which means repeating the titration side effects. Most patients who restart lose the regained weight within 3 to 6 months.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022.
4. Chen Y et al. Real-world outcomes of tirzepatide discontinuation: a retrospective cohort study. Diabetes Obes Metab. 2025.
5. Wilding JPH et al. Predictors of weight maintenance after GLP-1 receptor agonist discontinuation. Lancet Diabetes Endocrinol. 2024.
6. Thompson R et al. Predictors of weight loss maintenance after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. Obesity Reviews. 2025.
7. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. Kadowaki T et al. Efficacy and safety of tirzepatide as add-on to SGLT2 inhibitor in Japanese participants with type 2 diabetes (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
13. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
14. American College of Gastroenterology. Clinical Guidelines: Obesity Management. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.